A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

This study is testing a new antibody drug called HMBD-001 (which targets a cancer-promoting protein called HER3) in combination with chemotherapy (docetaxel) and/or another targeted drug (cetuximab) in people with advanced squamous cell cancers including lung cancer, head and neck cancer, esophageal cancer, skin cancer, or cervical cancer. **You may be eligible if...** - You are 18 or older with advanced squamous cell cancer (lung, head and neck, esophageal, skin, or cervical) - You are in good general health (ECOG 0–1) - All standard treatments have been exhausted or refused - You have at least one measurable tumor - Your life expectancy is at least 3 months - You are willing to provide a fresh tumor biopsy sample **You may NOT be eligible if...** - You have previously received HMBD-001, docetaxel (for the lung cancer arm), cetuximab, or any HER2/HER3/EGFR-targeting drug (with some exceptions) - You have had a recent COVID-19 infection (within 3 months) or vaccination (within 14 days) - You are pregnant or breastfeeding - You have active HIV, hepatitis B or C - You have symptomatic brain metastases - You take strong inhibitors or inducers of a liver enzyme called CYP3A4 Talk to your doctor to see if this trial is right for you.